Valproic acid treatment is associated with altered leukocyte subset development

Area of Science:

• Hematology
• Neuroscience
• Pharmacology

Background:

• Valproic acid (VPA) is a long-standing treatment for epilepsy and psychiatric conditions.
• Long-term VPA use is associated with hematological toxicity, notably neutropenia.
• VPA also functions as a histone deacetylase inhibitor (HDACi), investigated for hematological malignancy treatment.

Purpose of the Study:

• To investigate the specific effects of VPA on normal hematopoiesis and hematological malignancies.
• To analyze VPA's impact on white blood cell subsets in patients undergoing treatment for neurological or psychiatric disorders.

Main Methods:

• Analysis of patient data from a large population treated for neurological or psychiatric disorders.
• Evaluation of VPA's effects on neutrophil and lymphocyte subset counts.

Main Results:

• VPA treatment significantly affects neutrophil counts in patients.
• VPA treatment also impacts lymphocyte subset counts.
• Findings align with previous in vitro studies showing VPA affects myeloid progenitor differentiation.

Conclusions:

• VPA influences both neutrophil and lymphocyte populations in patients treated for neurological/psychiatric conditions.
• These findings highlight VPA's broader impact on hematopoiesis beyond its intended therapeutic effects.
• Understanding VPA's hematological effects is crucial for managing patient safety and exploring its therapeutic potential in oncology.